# Modelling red blood cell survival data



## Julia Korell<sup>1</sup>, Frederiek Vos<sup>1,2</sup>, Carolyn Coulter<sup>1</sup>, John Schollum<sup>2</sup>, Robert Walker<sup>2</sup>, Stephen Duffull<sup>1</sup>

1) School of Pharmacy, University of Otago, Dunedin, New Zealand ~ julia.korell@otago.ac.nz 2) Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand



### Background

- Survival of red blood cells (RBCs) is decreased in anaemia of chronic kidney disease (CKD) due to either:<sup>1</sup>
  - increase in random destruction.
  - accelerated senescence.
- Commonly, only a mean RBC lifespan value is determined based on RBC labelling experiments.<sup>2</sup>

#### Results

- Two-stage approach:
  - Estimation of random destruction preferred in majority of individuals (11 out of 14 in both groups).
  - Significant reduction in RBC survival in CKD patients: -28% compared to healthy controls (p = 0.0002).

 $\Rightarrow$  Better insight into the processes of RBC destruction is desirable.

- A statistical model for the survival time of RBCs has been developed based on the plausible physiological processes of RBC destruction:<sup>3</sup>
  - Early destruction of unviable RBCs, reduced lifespan of misshapen RBCs, random destruction and senescence.
- The model accounts for short-comings associated with known RBC labelling techniques, such as random labelling with radioactive chromium (<sup>51</sup>Cr).<sup>4</sup>

## **Objectives**

- To apply the previously developed model for RBC survival to clinical data.
- To investigate differences in the RBC lifespan in anaemic CKD patients compared to healthy controls.



- Population analysis:
  - A combined error model best described the data.
  - Preference for estimating random destruction confirmed.
  - Only CKD was found to be a significant covariate in the full model.
  - Mean RBC lifespan in CKD = 56.2 days, controls = 69.4 days.

Table II: PopulationApproach Results	$\hat{\overline{\Theta}}$	Ω	Mean LS	CV% <sub>prop</sub>	$\sigma_{add}{}^2$
Base model	0.0133 days <sup>-1</sup>	0.1296	56.0 days	2.27	0.0234
Full model	$0.0106 days^{-1}$	0 0721	60 1 dave	2.05	0 0256

#### **Materials & Methods**

• Available RBC survival data using <sup>51</sup>Cr labelling method:<sup>5</sup>

<b>Table I: Demographics</b>	<b>CKD group</b> $(n = 14)$	<b>Controls</b> (n = 14)
Age (years) ±SD	$57.2\pm8.6$	$57.3\pm7.9$
Sex (M:F)	8:6	8:6
Haemoglobin <sup>*</sup> (g/L) ±SD	$122 \pm 12$	$143 \pm 10$
*p < 0.0001		

- Two estimation scenarios were considered based on the model:
  - Estimating the main parameter controlling senescence.
  - Estimating the parameter controlling random destruction.
- Two analysis methods were used:
  - 1. A classical two-stage approach using generalized least squares.
    - $\Rightarrow$  Preference towards one of the scenarios across the individuals?
  - 2. A full population approach using MONOLIX 1.1.<sup>6</sup>  $\Rightarrow$  CKD and sex tested as covariates.







- RBC survival in CKD patients decreased by 20-30%.
- Goodness of fit was assessed based on objective function value and visual predictive checks.
- Wald test and likelihood ratio test were used to assess significance of the tested covariates.
- $\Rightarrow$  Increase in random destruction the preferred underlying mechanism.
- Initial over-prediction due to non-specific loss of label.  $\Rightarrow$  Care should be taken when interpreting RBC lifespan values.



1. Loge J, et al. (1958). Am. J. Med. 24:4-18 4. Korell J, et al. (2010). PAGE 19 Abstr 1701, Berlin, Germany. 2. ICSH (1980). Br. J. Haematol. 45(4):659-666 5. Vos F, et al. (2011). Am. J. Kidney Dis. (accepted) 3. Korell J, et al. (2011). J. Theor. Biol. 268(1):39-49 6. Lavielle M (2005) MONOLIX 1.1. User manual.

**Otago Pharmacometrics Group** ~ www.pharmacometrics.co.nz